Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;23(8):1390-1405.
doi: 10.1111/pedi.13451.

ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring

Martin Tauschmann  1 , Gregory Forlenza  2 , Korey Hood  3 , Roque Cardona-Hernandez  4 , Elisa Giani  5 , Christel Hendrieckx  6   7 , Daniel J DeSalvo  8 , Lori M Laffel  9   10 , Banshi Saboo  11 , Benjamin J Wheeler  12   13 , Dmitry N. Laptev  14 , Iroro Yarhere  15 , Linda A DiMeglio  16
Affiliations

ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring

Martin Tauschmann et al. Pediatr Diabetes. 2022 Dec.
No abstract available

Keywords: CGM; T1D; adolescents; children; continuous glucose monitor; diabetes technology; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Martin Tauschman reports having received speaker honoraria from Eli Lilly, Medtronic, and NovoNordisk. Martin Tauschman has served on an advisory board of Abbott. Daniel J. DeSalvo has served as an independent consultant for Dexcom and Insulet. Lori M. Laffel is a consultant/advisor to Dexcom, Insulet, Medtronic, and Roche. Dmitry N. Laptev has received honoraria for participation on advisory boards for Abbott, Novo Nordisk, Sanofi, Eli Lilly, and LifeScan and as a speaker for Abbott, LifeScan, Medtronic, Novo Nordisk, Sanofi, and Roche. Linda A. DiMeglio has consulted for Vertex, served on Mannkind, Merck, and Abata advisory boards, and received research support to her institution from Caladrius, Lilly, Mannkind, Medtronic, Provention, and Zealand All other authors have no relevant COI to report.

References

    1. Diabetes Control and Complications Trial Research Group , Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med. 1993;329(14):977‐986. doi:10.1056/nejm199309303291401 - DOI - PubMed
    1. Cardona‐Hernandez R, Schwandt A, Alkandari H, et al. Glycemic outcome associated with insulin pump and glucose sensor use in children and adolescents with T1D. Data from the international pediatric registry SWEET. Diabetes Care. 2021;44(5):1176‐1184. doi:10.2337/dc20-1674 - DOI - PubMed
    1. Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta‐analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146‐1156. doi:10.2337/dc19-1459 - DOI - PubMed
    1. King F, Ahn D, Hsiao V, Porco T, Klonoff DC. A review of blood glucose monitor accuracy. Diabetes Technol Ther. 2018;20(12):843‐856. doi:10.1089/dia.2018.0232 - DOI - PubMed
    1. International Standards Organization . ISO 15197:2013. In vitro diagnostic test systems – requirements for blood glucose monitoring systems for self‐testing in managing diabetes mellitus. Accessed February 5, 2022. https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standa...